CHE Stock Recent News

Chemtrade Logistics Income Fund (OTC:CGIFF) Q2 2025 Earnings Conference Call August 15, 2025 10:00 AM ET Company Participants Rohit Bhardwaj - VP of Finance & CFO Scott William Rook - CEO, President & Trustee Conference Call Participants Benjamin Isaacson - Scotiabank Global Banking and Markets, Research Division Gary Ho - Desjardins Securities Inc., Research Division Hamir Patel - CIBC Capital Markets, Research Division Joel Jackson - BMO Capital Markets Equity Research Nelson Ng - RBC Capital Markets, Research Division Steven P. Hansen - Raymond James Ltd.

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has formally authorized an additional $300 million for stock repurchase under Chemed's existing share repurchase program. These shares repurchases will be funded through a combination of cash generated from operations as well as utilization of its revolving credit facility. The Board of Directors has declared a quarterly cash dividend of 60-cents per share on the Company's capital stock, payab.

MIRAMAR, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- VITAS Healthcare, one of the nation's leading providers of hospice and palliative care, and a subsidiary of Chemed Corporation (NYSE: CHE), today announced that Nicholas M. Westfall will step down as chairman and chief executive officer to pursue other personal and professional opportunities. Joel L. Wherley, president and chief operating officer, was appointed by the Board to succeed Westfall as chief executive officer of VITAS Healthcare.

Chemed Corporation (NYSE:CHE ) Q2 2025 Earnings Conference Call July 30, 2025 10:00 AM ET Company Participants Holley Schmidt - Corporate Participant Kevin J. McNamara - CEO, President & Director Michael D.

Chemed (CHE -9.17%) -- home to hospice care provider Vitas Healthcare and Roto-Rooter -- saw its shares decline 9% as of 1 p.m. ET on Wednesday, according to data provided by S&P Global Market Intelligence.

Chemed (CHE) came out with quarterly earnings of $4.27 per share, missing the Zacks Consensus Estimate of $4.78 per share. This compares to earnings of $5.47 per share a year ago.

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation's largest providers of end-of-life care, and Roto-Rooter, the nation's largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its second quarter ended June 30, 2025, versus the comparable prior-year period. Results for Quarter Ended June 30, 2025 Consolidated operating results: Revenue increased 3.8.

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Astrana Health, Inc. (ASTH) and Chemed (CHE). But which of these two stocks offers value investors a better bang for their buck right now?

Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Chemed Corporation's diversified revenue streams from VITAS Healthcare and Roto-Rooter provide a strong competitive advantage and resilience against sector-specific risks. Recent VITAS acquisition and expansion, along with robust Q1 results, highlight the company's growth potential and operational strength, especially in hospice care. My DCF analysis suggests Chemed is undervalued by over 50%, with a fair value estimate of $744 per share, supporting a buy rating.